US EditionPublished • loading... • Updated
First Patient Dosed in Trial of KINE-101 for CIDP
Summary by Rare Disease Advisor
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
First Patient Dosed in Trial of KINE-101 for CIDP
The first patient in a new phase 1b/2a clinical trial to investigate KINE-101 for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) has been dosed, according to a press release from the treatment’s developer, Kine Sciences. The new trial is a dose escalation trial and will investigate increasing doses of KINE-101 in Korean patients with CIDP who have already received at least 1 frontline therapy. Read more about CIDP expe…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
